A new study offers a significant advancement in the treatment of acute pulmonary embolism (PE), a potentially life-threatening condition where blood clots block arteries in the lungs. Results from the global, randomized HI-PEITHO trial demonstrate that Boston Scientific’s Ekos system, which combines targeted thrombolytic delivery with ultrasound, is superior to standard anticoagulation treatment alone for patients with intermediate-risk PE. This finding could reshape clinical guidelines and improve outcomes for a condition that affects hundreds of thousands of people annually.
Pulmonary embolism is the third leading cause of cardiovascular death, according to the Centers for Disease Control and Prevention. Current medical guidelines recommend anticoagulation – blood thinners – as the first line of defense for patients across all risk levels. However, anticoagulation doesn’t always rapidly clear the blockage, and can leave patients vulnerable to long-term complications or even death. The Ekos system offers a minimally invasive alternative, aiming to dissolve the clot more quickly and effectively.
How the Ekos System Works
The Ekos system, a form of interventional cardiology, delivers a low dose of thrombolytic medication – a “clot-busting” drug – directly to the site of the pulmonary embolism. Crucially, it pairs this delivery with ultrasound energy. This ultrasound helps to disperse the medication throughout the clot, accelerating its breakdown. The system is designed to minimize the overall dosage of thrombolytics needed, potentially reducing the risk of bleeding, a common and serious side effect of these medications. “The goal is to get the medication where it needs to be, in a targeted way, and enhance its effectiveness,” explains Dr. Riyaz K. Bashir, a leading interventional cardiologist and investigator in the HI-PEITHO trial.
HI-PEITHO Trial Results: A Clear Benefit
The HI-PEITHO trial, involving 544 patients with intermediate-risk PE across 59 centers in the United States and Europe, showed a statistically significant benefit for those treated with the Ekos system in combination with anticoagulation. The primary endpoint – a composite of PE-related mortality, non-fatal hemodynamic decompensation (a dangerous decline in heart and lung function), and non-fatal symptomatic recurrent PE within seven days – occurred in 4.0% of patients in the Ekos group compared to 10.3% in the anticoagulation-only group (P=0.005). This represents a 61% reduction in events.
the study revealed a lower rate of hemodynamic decompensation in the Ekos group (3.7% vs. 10.3%). This is particularly important, as such events can lead to severe complications requiring emergency intervention. Perhaps most reassuringly, the trial reported no instances of intracranial hemorrhage – bleeding in the brain – within 30 days in either treatment group. This addresses a major concern associated with thrombolytic therapy.
Understanding Intermediate-Risk PE
It’s important to understand the categorization of PE risk. Patients are typically classified as low, intermediate, or high risk based on factors like blood pressure, heart rate, and the extent of the clot. Intermediate-risk PE represents a significant challenge for clinicians, as these patients are more ill than those at low risk, but may not be critically unstable enough to warrant the most aggressive interventions, such as surgical clot removal. The HI-PEITHO trial specifically focused on this intermediate-risk population, offering a new treatment option where options were previously limited.
Collaboration and Future Directions
The HI-PEITHO trial was a collaborative effort led by Boston Scientific, in partnership with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of Mainz. The PERT Consortium is a multidisciplinary group dedicated to improving the care of patients with PE. The study also involved collaboration with the international PEITHO network. Researchers will continue to follow patients for up to a year after treatment to assess long-term outcomes and durability of the observed benefits.
The findings from the HI-PEITHO trial are expected to prompt discussions among medical societies and potentially lead to updates in clinical practice guidelines for the management of acute pulmonary embolism. While anticoagulation remains a cornerstone of treatment, the Ekos system now offers a valuable alternative for carefully selected patients, potentially reducing morbidity and mortality associated with this serious condition.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next step will be to notice how these findings translate into real-world clinical practice and whether broader adoption of the Ekos system leads to improved outcomes for patients with pulmonary embolism. We will continue to follow this story as it develops.
What are your thoughts on this new treatment option? Share your comments below, and please share this article with anyone who might find it helpful.
Keep reading
